Form 4 for VCYT VERACYTE, INC.
Accepted 2023-10-04 00:00:00 ET · period of report 2023-10-02 · accession 0001384101-23-000155 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-04 | 2023-10-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | A - Grant | $0.00 | +53.2K | 53.2K | New | $0 |
| D | 2023-10-04 | 2023-10-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | A - Grant | $0.00 | +85.9K | 85.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-02 | A | A | 53,182 | $0.00 | 53,182 | D | — | — | (F1) Restricted stock units awarded on October 2, 2023 vest 25% on December 2, 2024 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2023-10-02 | A | A | 85,858 | $0.00 | 85,858 | D | $21.96 · — to 2033-10-02 | 85,858 Common Stock | (F2) The option becomes exercisable as to 25% of the shares on October 2, 2024, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. |